SEC Form 4 · accession 0001144204-16-106801
IMMUNE PHARMACEUTICALS INC · IMNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Miri Ben-Ami
Officer — See Remarks
Period of report
Jun 1, 2016
Accepted (ET)
Jun 3, 2016 · 4:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001208261
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $0.40 | Jun 1, 2016 | A | 180,000 | A | — | Jun 1, 2026 | Common Stock | 180,000 | 580,000 | D |
Explanation of responses
- F1The stock options shall vest over a period of three years, with 1/3 of the options vesting on the first anniversary of the date of grant and the remainder vesting quarterly over the following two-year period.
Remarks
Title: President of Immune Pharmaceuticals Ltd.